Al-Ola A Abdallah, Associate Professor at the University of Kansas Medical Center, shared on X:
“84 patients with Penta-refractory, BCMA-exposed myeloma with secondary PCL: brief teclistamab, stopped for infections—still in remission 44 months off therapy!
As BCMA BiTE combinations move earlier, we should study de-escalation and MRD-guided treatment discontinuation.”
Title: Teclistamab Dosing Strategies in Relapsed/Refractory Myeloma: A Real-World Comparison of Weekly and Biweekly Versus Fixed Intervals
Authors: Jordan Snyder, Shebli Atrash, Barry Paul, Abdullah Mohammad Khan, Alma Habib, Hira Shaikh, Christopher Strouse, Omar Alkharabsheh, Anita Mazloom, Nausheen Ahmed, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Anas Zayad, Joseph McGuirk, Yun Kyoung Tiger, Mansi R. Shah, Al-Ola Abdallah
Read the Full Article on Cancers
You can also read: MajesTEC-9: Teclistamab Monotherapy Demonstrates Superiority Over PVd/Kd in Earlier-Line RRMM
